International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale.

Challenge

Advanced AD therapy development required a prospective, longitudinal, multi-site real-world registry spanning all ages and both academic and community settings to generate the long-term comparative effectiveness, safety, and natural history data unobtainable from clinical trials.

Solution

The TARGET-DERM AD study was designed as an international longitudinal observational cohort with broad inclusion criteria, collecting up to 8 years of medical records alongside patient-reported outcomes and optional biospecimens from US, Canadian, and European sites.

Impact

Establishing the TARGET-DERM AD registry created the foundational real-world infrastructure for all subsequent AD natural history, treatment pattern, disparities, and PRO endpoint studies, directly enabling partnerships with AbbVie, Amgen, LEO Pharma, and other sponsors developing next-generation AD therapies.